InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,321.41
(
0.25%
)
US TECH 100
18,206.80
(
-0.14%
)
Dow Jones
39,872.99
(
0.17%
)
Brent Oil
82.28
(
-0.21%
)
Bitcoin
70,217.55
(
0.12%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

biotech_researcher

Send PM Follow Ignore
Followers 82
Posts 12444
Boards Moderated 0
Alias Born 07/25/2008

biotech_researcher

Re: None

Monday, 01/31/2011 1:01:49 PM

Monday, January 31, 2011 1:01:49 PM

Post# of 80490
Bellweather, it maybe as simple is that Merck doesn't have a plan quite yet. I think the Endo results are certainly good enough to move to a phase III trial in a VERY difficult cancer to treat.. What an opportunity for them to have a first mover advantage... it just takes time

They probably just don't have all their ducks aligned in order yet.. However, time is ah' wasting..
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up